Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
- 1 December 1991
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 68 (15), 1436-1446
- https://doi.org/10.1016/0002-9149(91)90276-q
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Efficacy and safety of pravastatin in patients with primary hypercholesterolemia: II. Once-daily versus twice-daily dosingAtherosclerosis, 1990
- Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular DiseaseNew England Journal of Medicine, 1990
- Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart StudyThe American Journal of Cardiology, 1989
- Serum lipids and lipoproteins after myocardial infarction: Associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction StudyAmerican Heart Journal, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MENThe Lancet, 1986
- Natural history of myocardial infarction in the coronary drug project: Long-term prognostic importance of serum lipid levelsThe American Journal of Cardiology, 1978
- Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortalityJournal of Chronic Diseases, 1978
- Ischaemic Heart Disease: A Secondary Prevention Trial Using ClofibrateBMJ, 1971
- The Oslo Diet-Heart StudyCirculation, 1970